|
Is there any possibility to generate the N-Desmethyl Tramadol in formulation?
|
|
3
|
138
|
February 21, 2025
|
|
N-nitroso Torasemide Impurity formation and control
|
|
25
|
1896
|
February 21, 2025
|
|
Nitrosamines et énantiomères
|
|
2
|
209
|
February 18, 2025
|
|
How to calculate the Limit of Nitrosamines from excipients?
|
|
5
|
472
|
February 4, 2025
|
|
What is CPCA Score for “N-nitroso of 3-Amino-1,2,4-triazole"
|
|
7
|
351
|
January 30, 2025
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
18
|
2796
|
January 30, 2025
|
|
Risk Assessment and Management Strategy of Two New Nitrosamine Drug Substance Related Impurities (NDSRIs) in a Pharmaceutical Drug Product for the Treatment of a Rare Disease- from Prediction to Control-Pub
|
|
0
|
373
|
January 29, 2025
|
|
EMA nitrosamine Q&A Appendix 1 rev.7 published on Dec 13, 2024
|
|
8
|
1314
|
January 27, 2025
|
|
🛑 N-nitroso Ticagrelor
|
|
16
|
3063
|
January 23, 2025
|
|
FREE Lhasa Webinar | Nitrosaminas en el horizonte: ¿Está preparado? 🇲🇽
|
|
1
|
204
|
January 22, 2025
|
|
Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific Acceptable Intakes-Pub
|
|
10
|
669
|
January 20, 2025
|
|
Acceptable Intake N-Nitrosobiotin (N-Nitrosamide)
|
|
2
|
200
|
January 13, 2025
|
|
SCIEX Webinar: Unlocking precision: nitrosamine and NDSRI analysis(16.1.2025 10:30 CET)
|
|
0
|
274
|
January 12, 2025
|
|
Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation
|
|
17
|
3909
|
January 10, 2025
|
|
The quagmire with the interim limit of nitroso duloxetine
|
|
0
|
239
|
January 6, 2025
|
|
FDA Updates Recall on Blood Pressure Medication Due to Possible Carcinogen
|
|
3
|
837
|
December 27, 2024
|
|
Chemistry of N-Nitroso Ivacaftor
|
|
7
|
1108
|
December 18, 2024
|
|
Limit of N-nitroso morpholine in Rocuronium Br
|
|
0
|
81
|
December 12, 2024
|
|
Autonomous CPCA Web-based calculator FREE
|
|
31
|
5494
|
December 12, 2024
|
|
📅 Updates on Approaches to Acceptable Intakes of Nitrosamine Drug Substance Related Impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products(CRCG)
|
|
35
|
2959
|
December 3, 2024
|
|
N-Nitroso Sertraline
|
|
7
|
386
|
November 27, 2024
|
|
N-Nitroso Metoprolol
|
|
0
|
122
|
November 20, 2024
|
|
Analytical procedure development and proposed established conditions: A case study of a mass spectrometry based NDSRI analytical procedure -Pub
|
|
19
|
1700
|
November 6, 2024
|
|
⁉️ Duloxetine Impurity NDSRI
|
|
7
|
676
|
November 1, 2024
|
|
Hypothetical Nitrosamine in 1-H Indazole / CPCA Approach
|
|
3
|
125
|
October 31, 2024
|
|
📅 Analytical challenges and the effective management of nitrosamines: The evolving landscape of NDSRI analysis
|
|
3
|
527
|
October 30, 2024
|
|
N-Nitroso Desmethyl Tramadol
|
|
3
|
364
|
October 29, 2024
|
|
Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA) -Pub
|
|
0
|
175
|
October 29, 2024
|
|
Hexamethyldisilazane (HMDS) can form Nitrosamine Impurity?
|
|
7
|
513
|
October 29, 2024
|
|
N-Nitrosamine drug substance related impurities (NDSRIs) – A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 Da -Pub
|
|
0
|
228
|
October 28, 2024
|